Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center.
COVID19
SARS-CoV-2
cancer patients
mRNA vaccine
solid tumors
vaccination
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
02
2022
accepted:
06
06
2022
entrez:
4
8
2022
pubmed:
5
8
2022
medline:
5
8
2022
Statut:
epublish
Résumé
Systemic immunosuppression characterizing cancer patients represents a concern regarding the efficacy of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, and real-world evidence is needed to define the efficacy and the dynamics of humoral immune response to mRNA-based anti-SARS-CoV-2 vaccines. We conducted an observational study that included patients with solid tumors who were candidates for mRNA anti-SARS-CoV-2 vaccination at the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. The primary objective was to monitor the immunologic response to the mRNA anti-SARS-CoV-2 vaccination in terms of anti-spike antibody levels. All the patients received two doses of the mRNA-1273 vaccine or the BNT162b2 vaccine. Healthcare workers served as a control group of healthy subjects. Among the 243 patients included in the present analysis, 208 (85.60%) and 238 (97.94%) resulted seroconverted after the first and the second dose of vaccine, respectively. Only five patients (2.06%) had a negative titer after the second dose. No significant differences in the rate of seroconversion after two vaccine doses were observed in patients as compared with the control group of healthy subjects. Age and anticancer treatment class had an independent impact on the antibody titer after the second dose of vaccination. In a subgroup of 171 patients with available data about the third timepoint, patients receiving immunotherapy with immune checkpoint inhibitors seem to have a higher peak of antibodies soon after the second dose (3 weeks after), but a more pronounced decrease at a late timepoint (3 months after). The systemic immunosuppression characterizing cancer patients did not seem to dramatically affect the humoral response to anti-SARS-CoV-2 mRNA vaccines in our population of patients with solid tumors. Further investigation is needed to dissect the interplay between immunotherapy and longitudinal dynamics of humoral response to mRNA vaccines, as well as to analyze the cellular response to mRNA vaccines in cancer patients.
Sections du résumé
Background
UNASSIGNED
Systemic immunosuppression characterizing cancer patients represents a concern regarding the efficacy of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, and real-world evidence is needed to define the efficacy and the dynamics of humoral immune response to mRNA-based anti-SARS-CoV-2 vaccines.
Methods
UNASSIGNED
We conducted an observational study that included patients with solid tumors who were candidates for mRNA anti-SARS-CoV-2 vaccination at the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. The primary objective was to monitor the immunologic response to the mRNA anti-SARS-CoV-2 vaccination in terms of anti-spike antibody levels. All the patients received two doses of the mRNA-1273 vaccine or the BNT162b2 vaccine. Healthcare workers served as a control group of healthy subjects.
Results
UNASSIGNED
Among the 243 patients included in the present analysis, 208 (85.60%) and 238 (97.94%) resulted seroconverted after the first and the second dose of vaccine, respectively. Only five patients (2.06%) had a negative titer after the second dose. No significant differences in the rate of seroconversion after two vaccine doses were observed in patients as compared with the control group of healthy subjects. Age and anticancer treatment class had an independent impact on the antibody titer after the second dose of vaccination. In a subgroup of 171 patients with available data about the third timepoint, patients receiving immunotherapy with immune checkpoint inhibitors seem to have a higher peak of antibodies soon after the second dose (3 weeks after), but a more pronounced decrease at a late timepoint (3 months after).
Conclusions
UNASSIGNED
The systemic immunosuppression characterizing cancer patients did not seem to dramatically affect the humoral response to anti-SARS-CoV-2 mRNA vaccines in our population of patients with solid tumors. Further investigation is needed to dissect the interplay between immunotherapy and longitudinal dynamics of humoral response to mRNA vaccines, as well as to analyze the cellular response to mRNA vaccines in cancer patients.
Identifiants
pubmed: 35923922
doi: 10.1177/17588359221108687
pii: 10.1177_17588359221108687
pmc: PMC9340426
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359221108687Informations de copyright
© The Author(s), 2022.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
JAMA Oncol. 2021 Oct 1;7(10):1507-1513
pubmed: 34236381
Lancet Oncol. 2021 Dec;22(12):1681-1691
pubmed: 34767759
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Ann Oncol. 2020 Oct;31(10):1320-1335
pubmed: 32745693
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
JAMA Oncol. 2021 Aug 1;7(8):1123-1125
pubmed: 34047766
Nat Cancer. 2021 Apr;2(4):392-399
pubmed: 34661163
ESMO Open. 2022 Feb;7(1):100350
pubmed: 34942438
N Engl J Med. 2021 Jul 22;385(4):320-329
pubmed: 34192428
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
J Virol Methods. 2021 Nov;297:114271
pubmed: 34461153
JAMA Oncol. 2021 Aug 1;7(8):1133-1140
pubmed: 34047765
J Immunother Cancer. 2021 Nov;9(11):
pubmed: 34845005
Cell Death Differ. 2019 Dec;26(12):2667-2681
pubmed: 30996287
Br J Haematol. 2022 Feb;196(3):548-558
pubmed: 34649298
J Clin Oncol. 2022 Jan 1;40(1):12-23
pubmed: 34752147
Eur J Cancer. 2021 Nov;157:124-131
pubmed: 34508994
Eur J Cancer. 2021 Nov;157:441-449
pubmed: 34601285
JAMA Oncol. 2021 Nov 1;7(11):1716-1718
pubmed: 34379092
N Engl J Med. 2021 Nov 4;385(19):1774-1785
pubmed: 34551225
Cancer Res. 2021 Dec 15;81(24):6273-6280
pubmed: 34759001
ESMO Open. 2021 Oct;6(5):100274
pubmed: 34597941
ESMO Open. 2021 Dec;6(6):100283
pubmed: 34634634
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Ann Oncol. 2022 Feb;33(2):158-168
pubmed: 34718117
Mol Cancer. 2021 Feb 25;20(1):41
pubmed: 33632261